- Aims of the study
- Steering Committee
- Unit role
- Partners and stakeholders
- Data sharing
The overall aims of the ADDITION study are to evaluate whether screening for prevalent undiagnosed type 2 diabetes is feasible, and whether subsequent optimised intensive treatment of diabetes, and associated risk factors, is feasible and beneficial.
Population-based screening in three European countries followed by an open, randomised controlled trial. Half of the patients diagnosed with type 2 diabetes in the ADDITION study went on to receive standard care for type 2 diabetes from their general practice following national guidelines. The other half received an intensive treatment programme to reduce their risk of cardiovascular disease. This programme aimed to educate and support general practitioners and practice nurses in target-driven management of blood glucose, blood pressure and cholesterol.
The primary endpoint was a combination of first cardiovascular event, including cardiovascular mortality, cardiovascular morbidity (non-fatal myocardial infarction and non-fatal stroke), revascularisation, and non-traumatic amputation.
The secondary outcomes were the individual components of the primary endpoint and all-cause mortality:
- Retinopathy (ETDRS scale)
- Neuropathy (Michigan questionnaire)
- Nephropathy (ACR, eGFR)
- Total, HDL and LDL cholesterol and triglycerides
- Blood pressure
- Smoking status
- Alcohol consumption
- Physical activity
- Health utility
- Diabetes-dependent quality of life
- Diabetes treatment satisfaction
- Functional status
- Self-reported history of CVD events / procedures
- Health service use
- Current mediation use
- Sleep disorder
- Anxiety and depression
Professor Annelli Sandbæk – Aarhus University
Professor Daniel Witte – Aarhus University
Professor Simon Griffin – University of Cambridge
Professor Nick Wareham – University of Cambridge
Professor Melanie J. Davies – University of Leicester
Professor Guy E.H.M. Rutten – University Medical Center Utrecht
Professor Kamlesh Khunti – University of Leicester
Data collection complete. 5-year follow up complete. 10-year follow up analysis in progress, 15-year follow up in set up.ess.
Unit led study with responsibility for data.
The study is sponsored by the University of Cambridge.
- MRC Epidemiology Unit at the University of Cambridge
- University Medical Center Utrecht
- University of Leicester
- Aarhus University
Unit involvement in ADDITION is funded by MRC core funding, plus grant support: Wellcome Trust (grant reference no: G061895), the Medical Research Council (grant reference no: G0001164), the NIHR Health Technology Assessment Programme (grant reference no: 08/116/300), National Institute for Health Research Programme Grants for Applied Research [RP-PG-0606-1259].National Health Service R&D support funding (including the Primary Care Research and Diabetes Research Networks) and the The University of Cambridge has received salary support in respect of Simon Griffin from the NHS in the East of England through the Clinical Academic Reserve.
Please see our Data Sharing portal